ImmunityBio, Inc. - Common Stock (NQ:IBRX)

10.29 +1.01 (+10.83%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ImmunityBio, Inc. - Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

23 24 Next >

ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code

May 12, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Stock Tumbles 18% After FDA Issues Refuse To File Letter: But Retail’s Positive ↗

May 05, 2025

ImmunityBio received an RTF letter regarding a supplemental biologics license application it filed for the use of ANKTIVA plus Bacillus Calmette-Guerin (BCG) in a specific case scenario of non-muscle...

Via Stocktwits

12 Health Care Stocks Moving In Monday's Intraday Session ↗

May 05, 2025

Via Benzinga

ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug ↗

May 05, 2025

ImmunityBio's ANKTIVA sBLA for papillary bladder cancer was rejected by the FDA despite prior support, prompting the company to request urgent talks.

Via Benzinga

Netflix, CNA Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

May 05, 2025

Via Benzinga

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency’s Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025

May 05, 2025

From ImmunityBio, Inc.

Via Business Wire

Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up

April 28, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting

April 21, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia

April 15, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor

April 08, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch

April 07, 2025

From ImmunityBio, Inc.

Via Business Wire

Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday ↗

March 27, 2025

Via Benzinga

ImmunityBio to Host Investor Day

March 26, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching

March 13, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug ↗

March 06, 2025

HC Wainwright initiates coverage on ImmunityBio with a Buy rating, citing Anktiva's growth potential. The firm projects $4.3 billion in sales, up from $137M in 2025.

Via Benzinga

This Tourmaline Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday ↗

March 06, 2025

Via Benzinga

Tesla Rebounds While Tariffs Weigh On Manufacturing: What's Driving Markets Monday? ↗

March 03, 2025

Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to 50.3%,...

Via Benzinga

ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024

March 03, 2025

From ImmunityBio, Inc.

Via Business Wire

IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

February 27, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer

February 27, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz Intensifies ↗

February 20, 2025

The company said that Merck’s TICE BCG shortages have created a significant hurdle for bladder cancer treatment.

Via Stocktwits

Garmin Posts Better-Than-Expected Results, Joins SolarEdge Technologies, Compass, Appian And Other Big Stocks Moving Higher On Wednesday ↗

February 19, 2025

Via Benzinga

FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage

February 19, 2025

From ImmunityBio, Inc.

Via Business Wire

Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins

February 18, 2025

Vancouver, BC – February 18, 2025 – USA News Group News Commentary – Despite optimism coming from the launch of Project Stargate (a $500 billion investment in AI data centers), there is still cause for...

Via FinancialNewsMedia

Topics Artificial Intelligence

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

February 13, 2025

From ImmunityBio, Inc.

Via Business Wire

Tesla, Nvidia, GM And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

February 03, 2025

Via Benzinga

ImmunityBio Stock Soars On BeiGene Tie-Up, Supply Deal: Retail Gets Dose Of Optimism ↗

January 29, 2025

The study will evaluate a combination therapy using BeiGene’s tislelizumab and ImmunityBio’s Anktiva for certain patients with advanced or metastatic non-small cell lung cancer

Via Stocktwits

Brinker International Posts Upbeat Results, Joins F5, T-Mobile US, Starbucks And Other Big Stocks Moving Higher On Wednesday ↗

January 29, 2025

Via Benzinga

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

January 29, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

January 27, 2025

From ImmunityBio, Inc.

Via Business Wire

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.